Molecular imaging manufacturer IBA Molecular has signed an agreement to install its first Proteus ONE unit in Europe, at Centre Antoine-Lacassagne, in Nice, France.
The agreement is worth 20 million euros ($25 million U.S.) and includes a 10-year service contract, IBA said.
The second-generation proton-beam system includes a pencil-beam scanning nozzle, enabling high-definition conformality to tumors as well as rapid dose delivery. It will complement the existing medium-energy biomedical cyclotron that has been used at the facility since 1991 to treat eye melanomas, IBA said.
